Investigational long-acting GLP-1 injectable: an upbeat news roundup of clinical presentations examining dosing strategies to support weight management across diverse patient groups.
Key Takeaways
- Weekly dosing in VESPER-1 yielded effective weight loss with favorable tolerability
- VESPER-3 monthly dosing produced placebo-adjusted weight loss up to 12.3% at 28 weeks
- Safety and tolerability were consistent with the established GLP-1 receptor agonist class